ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
FDA Approves Skytrofa (lonapegsomatropin-tcgd) for the Once-Weekly Treatment of Pediatric Growth Hormone Deficiency
August 26, 2021Ascendis Pharma A/S today announced that the U.S. Food and Drug Administration (FDA) has approved Skytrofa (lonapegsomatropin-tcgd) for the treatment of pediatric patients one year and older who weigh at least 11.5 kg (25.4 lb) . -
US clears Ascendis' once-weekly paediatric growth hormone injection
August 26, 2021Ascendis Pharma said Wednesday that the FDA has approved Skytrofa (lonapegsomatropin-tcgd) as a once-weekly treatment for paediatric patients aged one year and older who have growth failure due to inadequate secretion of endogenous growth hormone.
Pharma Sources Insight January 2025
